Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2209 ARTÍCULOS , VIENDO DEL 1936 AL 1950

Disruptive resting state networks characterizing depressive comorbidity in Alzheimer's disease and mild cognitive impairment

von Gal A, Papa D, D'Auria M, Piccardi L.

J Alzheimers Dis. 2025 Jul;106(1):18-37. doi: 10.1177/13872877251337770. Epub 2025 May 6.

Altered cerebellar activation patterns in Alzheimer's disease: An activation likelihood estimation Meta-Analysis

Bernard JA, Herrejon IA, An E, Cina Y, Dabbiru S, Dempsey J, Marrie E, Medina M, Praytor J.

Neuroimage Clin. 2025;46:103770. doi: 10.1016/j.nicl.2025.103770. Epub 2025 Mar 17.

The dual role of ACE2 in viral infections and neurodegeneration: mechanisms and therapeutic opportunities

Amelimojarad M, Amelimojarad M.

J Neurovirol. 2025 Oct;31(5):397-406. doi: 10.1007/s13365-025-01282-7. Epub 2025 Oct 14.

Speech pause and speech rate for evaluating Alzheimer's and mild cognitive impairment: A meta-analysis

Cohen AS, Divers R, Calamia M, Masucci M, Granrud OE, Corporandy A, Warren KK, Elvevåg B, Chandler C, Diaz-Asper C.

J Int Neuropsychol Soc. 2026 Jan;32(1):24-31. doi: 10.1017/S1355617725101677. Epub 2025 Dec 11.

Electroencephalogram features support the retrogenesis hypothesis of Alzheimer's disease: Exploratory comparison of brain changes in aging and childhood

Saraiva JA, Becker M, Dyrba M, Bölükbaş B, Salamone EM, Babiloni C, Kölch M, Hampel H, Teipel S, Kirste T, Berger C.

J Alzheimers Dis. 2025 Aug;106(4):1395-1414. doi: 10.1177/13872877251352119. Epub 2025 Jun 30.

Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

da Silva AMP, Falcão L, Virgilio Ribeiro F, Ogasawara Donato K, Machado Magalhães PL, Nascimento MDVS, Leite M, Lee Han M, Quiroga DG, de Souza Franco E, de Sousa Maia MB.

J Geriatr Psychiatry Neurol. 2026 May;39(3):249-260. doi: 10.1177/08919887251369893. Epub 2025 Aug 22.

Atrophy of the auditory cortex in Alzheimer's disease

Sousa Menezes A, Coelho A, Morais-Ribeiro R, Oliveira TG; Alzheimer’s Disease Neuroimaging Initiative.

Hear Res. 2025 Nov;467:109430. doi: 10.1016/j.heares.2025.109430. Epub 2025 Sep 14.

Cognitive Intra-individual Variability in Cognitively Healthy APOE ε4 Carriers, Mild Cognitive Impairment, and Alzheimer's Disease: a Meta-analysis

Aita SL, Del Bene VA, Knapp DL, Demming CE, Ikonomou VC, Owen T, Campbell IA, Wagaman BN, Borgogna NC, Caron JE, Roth RM, Hill BD.

Neuropsychol Rev. 2025 Dec;35(4):745-765. doi: 10.1007/s11065-024-09654-2. Epub 2024 Nov 21.

Task-based fMRI brain activation in mild cognitive impairment and Alzheimer's disease: an ALE meta-analysis

Lee ZL, Li JJ, Siew SKH, Billaud CHA, Yu J.

Geroscience. 2026 Apr;48(2):3069-3096. doi: 10.1007/s11357-025-01850-z. Epub 2025 Aug 29.

The Conceivable Role of Metabolic Syndrome in the Pathogenesis of Alzheimer's Disease: Cellular and Subcellular Alterations in Underpinning a Tale of Two

Alzarea EA, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Beshay ON, Batiha GE.

Neuromolecular Med. 2025 May 16;27(1):35. doi: 10.1007/s12017-025-08832-6.

A Study on Voice Measures in Patients With Alzheimer's Disease

Xiu N, Vaxelaire B, Li L, Ling Z, Xu X, Huang L, Sun B, Huang L, Sock R.

J Voice. 2025 Jan;39(1):286.e13-286.e24. doi: 10.1016/j.jvoice.2022.08.010. Epub 2022 Sep 21.

Translation of task-evoked negative BOLD response into aging and Alzheimer's disease: a systematic review of the current literature

Ghaderi Yazdi B, Razlighi QR.

J Transl Med. 2025 Jul 29;23(1):850. doi: 10.1186/s12967-025-06721-x.

Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria

Morotti A, Pilotto A, Zanola D, Galli A, Caratozzolo S, Gasparotti R, Padovani A.

Neurology. 2025 Jan 28;104(2):e210248. doi: 10.1212/WNL.0000000000210248. Epub 2024 Dec 30.

IL-24 ameliorates cognitive dysfunction via the inhibition PERK-eIF2α Signaling pathway in Alzheimer's disease

Du Y, Zheng X, Yue X, Fu P, Diao J, Zhang A, Cheng H, Yang H, Bi J, Zhou Q, Wang P.

Int Immunopharmacol. 2026 Jan 15;169:116039. doi: 10.1016/j.intimp.2025.116039. Epub 2025 Dec 18.

Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts

Lagarde J, Maiti P, Schonhaut DR, Blazhenets G, Zhang J, Eloyan A, Thangarajah M, Taurone A, Allen IE, Soleimani-Meigooni DN, Zeltzer E, Windon C, Abu Raya M, Vrillon A, Smith K, Shankar R, Amuiri A, Rocha S, Hammers DB, Dage JL, Nudelman KN, Kirby K, Aisen P, Koeppe R, Landau SM, Carrillo MC, Touroutoglou A, Brickhouse M, Vemuri P, Beckett L, Raman R, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Grant IM, Rogalski E, Johnson ECB, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Dickerson BC, Apostolova LG, La Joie R, Rabinovici GD; LEADS Consortium for the Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2025 Aug;98(2):236-248. doi: 10.1002/ana.27233. Epub 2025 Mar 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias